AWE 2025 Concludes: AI-Industry Synergy Unveils Vision for Smart Living Across All Scenarios

SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 23, the 2025 Appliance & Electronics World Expo (AWE2025) concluded at Shanghai New International Expo Centre after a four-day run. This year's event drew over 1,000 global leaders in home appliances and consumer electronics, and showcased tens of thousands of cutting-edge smart living products and solutions.

Haier introduced its pioneering "Eye of AI" technology, equipping smart devices not only to "process voice commands" but also to "visually interpret" their environments. Revolutionary applications include range hoods that track cooking pots, ovens that monitor grilling progress, and washing machines that analyze laundry cycles, all achieving effortless, hands-free appliance management. Huawei's upgraded Harmony Smart Home debuted experiential zones emphasizing intuitive voice control, air quality enhancement, and retrofit-friendly smart home solutions, redefining modern living. Hisense utilized its self-developed StarSea Large Model to evolve appliances from basic "functional tools" into proactive "AI companions", enhancing emotional intelligence and user-centric adaptability. Siemens' AI Vision simplifies cooking workflows; Gree's AI dynamic energy-saving technology enables instant efficiency on startup; Fotile unveiled the world's first AI-powered healthy cooking system, Healthy CookingGPT; and Robam premiered its "Culinary Master" AI model. Collectively, these innovations signal a transformative leap in AI-powered home technology.

Samsung's HoloDisplay uses 3D imaging to create floating holographic screens, while Sony has introduced an RGB high-density LED display system that delivers expanded color range, enhanced brightness, and precise control. Hisense unveiled the world's first 116-inch RGB-Mini LED TV (UX model), featuring their debut H7 AI imaging chip for unmatched color accuracy through RGB light-color synchronization. TCL also raised the bar with its Q10L series—the world's first fourth-gen QLED TVs, using "Myriad Zoning" technology to achieve more effective light control. Meanwhile, innovative devices like Huawei's foldable Pura X phone, RayNeo's X3 Pro AR glasses, and Shokz's OpenDots ONE earbuds are transforming how we experience sound and visuals.

First-time exhibitor Unitree introduced its G1 humanoid bot and nimble Go2 robotic dog. The event also spotlighted TCL's modular Ai Me companion robot, Haier and ROBOTERA's jointly developed home service robot "Xiaoxing," JD.com and Weilan Tech's collaborative robot dog, and humanoid "Xiaomai" developed by Dreame's subsidiary Magiclab. These intelligent, physical products are steadily moving from lab prototypes to everyday homes.

Amid the wave of AI-driven industrial integration, the "human-car-home" interconnected ecosystem has emerged as a central theme at AWE in recent years. Huawei highlighted several models under Harmony Intelligent Mobility Alliance (HIMA), showcasing a comprehensive "human-car-home" ecosystem through seamless integration of smartphones, vehicle interfaces, and smart home devices. As the first-time NEV exhibitor, BYD debuted its Leopard 8 featuring the "Lingyuan" intelligent vehicle-mounted drone system and Denza N9, a tech-forward, safety-optimized, multi-functional SUV. AWE2025 also features a special "Mobile Home" section for NEVs for the first time, displaying popular models from NIO, Li Auto, XPeng, Zeekr, and Great Wall Motor.

AWE2025 launched the "AWE Shopping Festival," a collaborative effort by CHEAA, CMG General Manager's Office, and AWE. The festival merged online and offline engagement strategies, combining entertaining content, livestream shopping, and financial incentives to drive participation. The initiative partnered with leading platforms including JD.com, Tmall, Douyin, Suning, Xiaohongshu, Kuaishou, and Bilibili to launch extensive promotional campaigns.

AWE2025 concluded on a high note. Moving forward, AWE will remain a global trendsetter for the industry, driving high-end, intelligent, and eco-friendly upgrades while accelerating technological and product innovation. See you at AWE2026!

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

AWE 2025 Concludes: AI-Industry Synergy Unveils Vision for Smart Living Across All Scenarios

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com. 

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team